基于整合药理学研究参麦注射液治疗心力衰竭的生物作用机制

Study on the biological mechanism of the action of Shenmai injection treatment of chronic heart failure by using integrative pharmacology

本文利用中医药整合药理学研究平台(TCMIP V2.0)视角,探索参麦注射液治疗心衰的作用机制,借助于本平台的分析功能,构建参麦注射液治疗心衰的"中药-化学成分-核心靶标-关键通路"多维网络,从不同的角度探索参麦注射液干预心衰的潜在分子机制。在TCMIP V2.0分析参麦注射液治疗心衰的分子机制研究结果表明,参麦注射液干预心衰的化学成分主要集中在人参皂苷和麦冬皂苷类化合物。药物与疾病的共有核心靶标包括钠/钾离子转运ATP酶α1肽(ATP1A1)、肿瘤坏死因子(TNF)和磷脂酰肌醇-4,5-二磷酸3-激酶催化亚单位,γ亚型(PIK3CG)。涉及cAMP信号通路、雌激素信号通路、TNF信号通路和心肌细胞肾上腺素能信号转导。

From the perspective of traditional Chinese medicine Integrated pharmacology research platform(TCMIP V2.0),this paper explored the mechanism of Shenmai injection in the treatment of heart failure.With the analysis function of this platform,we constructed a multi-dimensional network of"traditional Chinese medicine-chemical components-core target-key pathway",and explored the potential molecular mechanism of Shenmai injection in treating heart failure from different perspectives.In TCMIP V2.0,the molecular mechanism of Shenmai injection in the treatment of heart failure was analyzed.The results showed that the chemical components of Shenmai injection mainly concentrated in ginsenosides and ophiopogon saponins.The common core targets of drugs and diseases include Na(+)/K(+)ATPase 1(ATP1 A1),tumor necrosis factor(TNF)and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma(PIK3 CG).It involves cAMP signaling pathway,estrogen signaling pathway,TNF signaling pathway and adrenergic signal transduction in cardiomyocytes.